Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anal Fissure Pain
Progress reported on Cellegesic phase III trial
September 1st, 2003
Cellegy Pharmaceuticals, Inc., (CLGY) announced that it has made considerable progress with a new 150-patient phase III clinical trial with Cellegesic (nitroglycerin ointment) for the treatment of pain associated with chronic anal fissures. There are currently no U.S. Food and Drug Administration (FDA) approved drug therapies for this condition, which afflicts approximately 700,000 people in the United States. This new study is intended to confirm the statistically significant pain reduction seen in the previous two phase III studies. This trial's protocol and logistics are designed to expedite completion of the study and address FDA requirements...
Source: Health & Medicine Week (2003-09-01)
|
